In 2015, the Pierre Fabre Group signed an international partnership with Array BioPharma, an American biotech company based in Boulder, Colorado. Aim: to develop and market a targeted oncology therapy, combining two next-generation molecules. In late 2018, the European Commission granted marketing authorization for this new treatment for adult patients suffering from advanced BRAF-mutant melanoma.